Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism

Chest

Volumn 126, Issue 3, 2004, Pages 687-692

  Inoue, Hiroshi ^a   Nozawa, Takashi ^a   Okumura, Ken ^b   Jong Dae, Lee ^c   Shimizu, Akihiko ^d   Yano, Katsusuke ^e  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

^d YAMAGUCHI UNIVERSITY   (Japan)

^e NAGASAKI UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Embolism; Hemostatic markers; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA THROMBOGLOBULIN; D DIMER; PROTHROMBIN; PROTHROMBIN FRAGMENT 1; PROTHROMBIN FRAGMENT 2; THROMBOCYTE FACTOR 4; TICLOPIDINE; UNCLASSIFIED DRUG;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; EMBOLISM; FEMALE; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THROMBOCYTE ACTIVATION; THROMBOGENESIS; THROMBUS;

EID: 4544308666     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.3.687     Document Type: Article

References (20)

1. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1.066 patients from 3 clinical trials. Arch Intern Med 1998; 158:1316-1320
2. Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1998; 31:1622-1626
3. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449-1457
4. Cairns JA. Atrial fibrillation: antithrombotic therapy. In: Yusuf S, Cairns JA, Camm AJ, et al, eds. Evidence based cardiology. 2nd ed. London, UK: BMJ Books, 2003; 548-555
5. Kumagai K, Fukunami M, Ohmori M, et al. Increased intracardiovascular clotting in patients with chronic atrial fibrillation. J Am Coll Cardiol 1990; 16:377-380
6. Lip GYH, Lip PL, Zarifis J, et al. Fibrin d-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94:425-431
7. Lip GYH, Lowe GDO, Rumley A, et al. Fibrinogen and fibrin d-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J 1996; 131:724-730
8. Sohara H, Amitani S, Kurose M, et al. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29:106-112
9. Yamamoto K, Ikeda U, Fukazawa H, et al. Effects of aspirin on status of thrombin generation in atrial fibrillation. Am J Cardiol 1996; 77:528-530
10. Li-Saw-Hee FL, Blann AD, Lip GYH. Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation. Am J Cardiol 2000; 86:795-797
11. Feng D, D'Agostino RB, Silbershatz H, et al. Hemostatic state and atrial fibrillation (The Framingham Offspring Study). Am J Cardiol 2001; 87:168-171
12. Conway DSG, Pearce LA, Chin BSP, et al. Plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 102:1962-1967
13. Nozawa T, Inoue H, Iwasa A, et al. Effects of anticoagulation intensity on hemostatic markers in patients with non-valvular atrial fibrillation. Circ J 2004; 68:29-34
14. Nakagawa K, Hirai T, Shinokawa N, et al. Aortic spontaneous echocardiographic contrast and hemostatic markers in patients with nonrheumatic atrial fibrillation. Chest 2002; 121:500-505
15. Kistler JP, Singer DE, Millenson MM, et al. for the BAATAF Investigators: effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. Stroke 1993; 24:1360-1365
16. Kamath S, Blann AD, Chin BSP, et al. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002; 40:484-490
17. Heppell RM, Berkin KE, McLenachan JM, et al. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997; 77:407-411
18. Shinohara H, Fukuda N, Soeki T, et al. Relationship between flow dynamics in the left atrium and hemostatic abnormalities in patients with nonvalvular atrial fibrillation. Jpn Heart J 1998; 39:721-730
19. Li-Saw-Hee FL, Blann AD, Lip GYH. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31:828-833
20. Koefoed BG, Feddersen C, Gullov AL, et al. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation. Throrab Haemost 1997; 77:845-848